Evaluating an Alternative Clinical Genetics Cancer Care Deliver Model
Study Details
Study Description
Brief Summary
To evaluate an alternative clinical genetics cancer care delivery model, using non-genetic providers to introduce and order genetic testing. 250 prostate and 250 pancreatic patients will be recruiting. They will undergo genetic testing and complete study questionnaires. Results from this pilot study will be used to inform the strategies used by the Clinical Risk Evaluation Program (CREP) Genetic Counelors (CGS) and GI/GU physicians to deliver genetic testing and return genetic risk information to patients with prostate or pancreatic cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- baseline to post-results change in distress levels [1-3months]
Change in distress levels (HADS-Anxiety) from Baseline to Time point #2 (post-disclosure) measured as an effect size among participants who receive a pathogenic variant(s), no pathogenic variant(s), and variant(s) of uncertain significance
- baseline to post-results change in distress levels [3 months]
Change in distress levels (HADS-Anxiety) from Baseline to Time point #3 (3 months post-disclosure) measured as an effect size among participants who receive a pathogenic variant(s), no pathogenic variant(s), and variant(s) of uncertain significance
Eligibility Criteria
Criteria
Inclusion Criteria:
-
• Penn patient age 18 years or older.
-
Diagnosed with prostate cancer or pancreas cancer.
-
Deemed to be clinically appropriate for multiplex genetic testing by their Urologic Cancer Program (GU) physician or Gastrointestinal Cancer Program (GI) physician at the Abramson Cancer
-
Agreed to receive clinical multiplex genetic testing from their physician.
-
English-fluent; the surveys were designed and validated in English and are not currently available in other languages.
Exclusion Criteria:
-
• Patients who do not or will not receive their ongoing cancer care at Penn
-
Major psychiatric illness or cognitive impairment that in the judgment of the study investigators or study staff would preclude study participation.
-
Any patients who are unable to comply with the study procedures as determined by the study investigators or study staff.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Penn Medicine - University of Pennsylvania | Philadelphia | Pennsylvania | United States | 19104 |
Sponsors and Collaborators
- Abramson Cancer Center of the University of Pennsylvania
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- UPCC 15917
- 828314